TNYANasdaq

Tenaya Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · DE · CIK 1858848

Discovering, developing, and delivering potentially curative therapies for heart disease

red 8-K · 90d

+ Watch View on EDGAR ↗

$171M

Market cap

$0.87

Last close

+2.4%

+10.6%

3.9M

Volume

Price$0.87+26.5%· 1Y

Volume

Jul 10L $0.55 · H $2.10Jul 10

Revenue & earnings

RevenueNet incomeLoss

Fundamentals & quality

Fundamentals not yet available for this company.

Similar companies

Comparable business profile · signals at a glance

EWTXEdgewise Therapeutics, Inc.$4.3B-6.1%BBIOBridgeBio Pharma, Inc.$15.1B-4.8%NTLAIntellia Therapeutics, Inc.$2.5B-7.9%MISTMilestone Pharmaceuticals Inc.$164.3M-2.3%EDITEditas Medicine, Inc.

Filings archive

Newest first · each with a one-line AI read · showing 10 of 104

Jun 29, 20268-KExecutive Change · Reg FD DisclosureTenaya Therapeutics, Inc. announced the appointment of Eric Hyllengren as Chief Financial Officer, who will also serve as Principal Financial Officer and Principal Accounting Officer, effective July 13, 2026. This appointment leads to the transition of the interim Principal Financial Officer and acting interim Principal Accounting Officer roles.May 29, 20268-KExecutive Change · Shareholder VoteTenaya Therapeutics, Inc. held its annual meeting of stockholders on May 27, 2026, where they voted on several proposals, including the election of directors and the approval of an amended equity incentive plan.May 6, 202610-Q10-QHere is a summary of the SEC periodic report for an investor: Tenaya Therapeutics reported a net loss of $19.3 million for the first quarter of 2026, a decrease from the $26.9 million net loss in the same period last year, primarily due to reduced operating expenses. The company ended the quarter with $80.9 million in cash and cash equivalents and believes this is sufficient to fund operations for at least the next twelve months.

Insider activity

Open-market buys & sells (Form 4) · trailing 12 months

0 bought · 5 sold

Net insider $ · by month

2025-11buys ▲ · sells ▼2026-02

Column Group Iii-A, Lp

TenPercentOwner

Sold$3.5M

8 sells

Tcg Opportunity Iii Gp, Llc

TenPercentOwner

Sold$2.4M

4 sells

Ali FarazC-suite

Chief Executive Officer

Sold$14K

4 sells

Tingley WhittemoreC-suite

Chief Medical Officer

Sold$6K

3 sells

Higa Tomohiro

SVP, Finance

Sold$4K

4 sells

Open-market buys & sells (Form 4, transaction codes P/S), aggregated per insider over the trailing 12 months. Source: SEC structured insider data.